Targeting NASH and other devastating fibro-inflammatory liver diseases

Promethera Biosciences is developing cell-based therapies to treat major acute and chronic liver diseases. Building on its research into immunomodulatory and antifibrotic allogeneic therapies, the biotech is running clinical development programs in acute-on-chronic liver failure (ACLF) and nonalcoholic steatohepatitis (NASH).

Like Comment
Page of
Go to the profile of Promethera


Promethera Biosciences is a global innovator in liver therapeutics whose mission is to enable patients to overcome acute and chronic liver diseases. Our lead clinical program, derived from our patented cell technology platform HepaStem, is designed to benefit from its immune-modulatory and anti-fibrotic properties. In addition to our cell-based pipeline we develop antibody technologies, such as the anti-TNF-R1 antibody Atrosimab, to complement and diversify our therapeutic options. We are a team of international experts operating out of R&D and GMP facilities in Mont-Saint-Guibert, Belgium, and Durham, NC, USA.

No comments yet.